Hit enter to search or ESC to close
NuView Life SciencesNuView Life Sciences
  • Home
  • About Us
    • Mission
    • Leadership
      • Management Team
      • Directors
      • Clinical Collaborators
      • Consultants
  • Products
    • In Vivo Diagnostics
    • In Vitro Diagnostics
    • Theranostics Applications
    • Why Research for New Diagnostics?
  • Pipeline
  • News
    • NuView Life Sciences in the News
    • Press Releases
  • Publications
  • Contact Us
NuView Life Sciences
Dec 20
Love0

Potential Radioisotope Shortage Looming, NuView Life Sciences Subsidiary Emerges as Industry Alternative

By Karla Jo Helms Press Releases

The recent shutdown of a major radioisotope production facility will potentially cause shortages of a vital medical isotope used worldwide in nuclear medicine procedures. US…

Read More
Dec 14
Love0

Emphasis On Precision Medicine, Moonshot Cancer Initiative Spark Diagnosis Advances

http://www.healthitoutcomes.com/doc/emphasis-on-precision-medicine-moonshot-cancer-diagnosis-advances-0001
Nov 28
Love0

NuView Life Sciences Liquid Biopsy Tech Changing the Cancer Diagnosis Industry

By Karla Jo Helms Press Releases

Traditional cancer diagnostic methods, including biopsies, are labor-intensive, expensive and invasive. NVLS is poised to change the way cancer is diagnosed with its new liquid…

Read More
Oct 25
Love0

U.S. Spends an Estimated $7.9 Billion on Negative Breast and Prostate Cancer Tests; NuView Life Sciences Poised to Change Cancer Diagnosis and Treatment

By Karla Jo Helms Press Releases

Traditional methods of diagnosing malignant cancer are invasive, expensive, and not always accurate. Now, a new way to identify cancer cells stands ready to change…

Read More
Mar 28
Love0

Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review)

By Karla Jo Helms Publications

This publication showed that VIP receptors are very important in the biology of many malignancies and are overexpressed in many tumors; thus, VIP receptors can…

Read More
Feb 28
Love0

VPAC1 Receptors for Imaging Breast Cancer:A Feasibility Study

By Karla Jo Helms Publications

This feasibility study demonstrated the compelling need for an innovative approach that would decrease the number of unnecessary benign biopsies while still detecting the malignancies….

Read More
Feb 28
Love0

99mTcLabeled Vasoactive Intestinal Peptide Analog for Rapid Localization of Tumors in Humans

By Karla Jo Helms Publications

In recent years, imaging tumors with receptor-specific biomolecules has been the focus of increasing interest. Vasoactive intestinal peptide (VIP)(VPAC) has a high affinity for specific…

Read More
Jan 28
Love0

Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor Subtypes in Human Tumors and Their Tissues of Origin

By Karla Jo Helms Publications

The evaluation of peptide receptors in man is needed not only to discover the physiological target tissues of a given peptide but also to identify…

Read More
Previous 1 … 4 5 6

Categories

  • News
  • NuView Life Sciences in the News
  • Press Releases
  • Publications

Recent Posts

  • NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer
  • Targeting VPAC1 Receptors for Imaging Glioblastoma
  • NuView Life Sciences Creates Subsidiary for Latin American Market
  • Jay Bishoff, MD, joins The Smith Institute for Urology
  • Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics

Archives

  • October 2022
  • January 2022
  • November 2021
  • August 2021
  • February 2021
  • January 2021
  • November 2020
  • August 2020
  • June 2020
  • May 2020
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • April 2019
  • March 2019
  • January 2019
  • November 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • March 2013
  • February 2013
  • February 2000
  • January 2000

NuView Life Sciences is a clinical stage oncology company addressing unmet medical needs.

Read More

Contact Address

NuView Life Sciences, Inc
1389 Center Drive, Suite 200
Park City, Utah 84098

Office: 435.647.9758 

Contact us:
admin@nuviewlifesciences.com

Media inquiries:
Jennifer K. Zimmons
jzimmons@zimmonsic.com

The most recent press

  • NuView Life Sciences Provides Corporate Update on NV-VPAC1 Theranostic for Breast Cancer October 5, 2022
  • NuView Life Sciences Creates Subsidiary for Latin American Market November 17, 2021

Quick Links

  • Home
  • About Us
  • Products
  • Pipeline
  • News
  • Publications

© 2023 NuView Life Sciences. Terms of Use

  • Home
  • About Us
    • Mission
    • Leadership
      • Management Team
      • Directors
      • Clinical Collaborators
      • Consultants
  • Products
    • In Vivo Diagnostics
    • In Vitro Diagnostics
    • Theranostics Applications
    • Why Research for New Diagnostics?
  • Pipeline
  • News
    • NuView Life Sciences in the News
    • Press Releases
  • Publications
  • Contact Us